Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
8 papers
Recent·Most cited
A. Priddey, M. X. H. Chen-Xu, D. J. Cooper, S. MacMillan, G. Meisl, C. K. Xu, M. Hosmillo, I. G. Goodfellow, R. Kollyfas, R. Doffinger, J. R. Bradley, I. I. Mohorianu, R. Jones, T. P. J. Knowles, R. Smith, V. Kosmoliaptsis
bioRxiv · Oct 22, 2023Immunology
G. Krainer, R. P. B. Jacquat, M. M. Schneider, T. J. Welsh, J. Fan, Q. A. E. Peter, E. A. Andrzejewska, G. Sneideriene, M. A. Czekalska, H. Ausserwoeger, L. Chai, W. E. Arter, K. L. Saar, T. W. Herling, T. M. Franzmann, , T. P. J. Knowles
This paper introduces smMDS, a method for digital sizing of proteins in solution, enabling sensitive and accurate measurement of protein sizes and interactions.
bioRxiv · Jul 12, 2023Biophysics
S. Fiedler, S. R. A. Devenish, A. S. Morgunov, A. Ilsley, F. Ricci, M. Emmenegger, V. Kosmoliaptsis, E. S. Theel, J. R. Mills, A. M. Sholukh, A. A. A. Aguzzi, A. Iwasaki, A. K. Lynn, T. P. J. Knowles
The paper links antiviral activity of therapeutic antibodies to their affinity and concentration by comparing them to serological fingerprints in convalescent sera.
bioRxiv · Feb 3, 2022Biochemistry
V. Denninger, C. K. Xu, G. Meisl, A. S. Morgunov, S. Fiedler, A. Ilsley, M. Emmenegger, A. Y. Malik, M. A. Piziorska, M. M. Schneider, S. R. A. Devenish, V. Kosmoliaptsis, A. Aguzzi, H. Fiegler, T. P. J. Knowles
This study uses microfluidic antibody-affinity profiling to assess cross-reactive antibodies against SARS-CoV-2 in convalescent patients and pre-pandemic sera, finding low affinity and concentration against SARS-CoV-2 spike protein.
bioRxiv · Jul 23, 2021 · PreprintBiophysics
S. Fiedler, V. Denninger, A. S. Morgunov, A. Ilsley, R. Worth, G. Meisl, C. K. Xu, M. A. Piziorska, F. Ricci, A. Y. Malik, S. R. A. Devenish, M. M. Schneider, V. Kosmoliaptsis, A. Aguzzi, A. Iwasaki, , T. P. J. Knowles
This study compares antibody escape mechanisms in SARS-CoV-2 alpha and beta variants, finding they use distinct strategies: alpha increases ACE2 binding affinity, while beta alters epitopes to reduce antibody access.
bioRxiv · Jul 23, 2021 · PreprintBiochemistry
H. C. Copley, L. Gragert, A. R. Leach, V. Kosmoliaptsis
The paper investigates how HLA class II polymorphism affects predicted CD4+ T-cell reactivity to SARS-CoV-2 across populations and individuals, finding similar population-level immunity despite individual variability.
bioRxiv · Dec 24, 2020Immunology
M. M. Schneider, T. Scheidt, A. J. Priddey, C. K. Xu, M. Hu, S. R. A. Devenish, G. Meisl, C. M. Dobson, V. Kosmoliaptsis, T. P. J. Knowles
This paper develops a microfluidic assay to directly measure antibody affinity and concentration in solution, applied to characterise alloantibody-HLA interactions in transplant patient sera.
bioRxiv · Sep 14, 2020 · PreprintBiophysics
D. H. Mallon, C. Kling, M. Robb, E. Ellinghaus, J. A. Bradley, C. J. Taylor, D. Kabelitz, V. Kosmoliaptsis
The paper develops a computational score to predict donor-specific alloantibody development based on HLA surface electrostatic potential differences between donor and recipient.
bioRxiv · Apr 4, 2018Immunology